MPM BioImpact Exits MBX, MoonLake, Crinetics in Q3, SEC Filing Shows
A November 14 disclosure details full sell-offs with estimated proceeds based on quarterly average prices.
Overview
- The fund sold all 1,294,416 shares of MBX Biosciences in the third quarter, an estimated $14.8 million transaction based on average prices.
- It disposed of 428,975 shares of Crinetics Pharmaceuticals, with an estimated value of $12.3 million using the same methodology.
- It exited 313,571 shares of MoonLake Immunotherapeutics, reflecting an estimated $14.8 million reduction in exposure.
- The combined estimated reduction across the three exits was roughly $41.9 million, calculated from quarterly average prices.
- MBX had represented about 2.6% of fund assets as of June, and late-November coverage describes the moves as portfolio repositioning drawn from the November 14 SEC filing.